Last reviewed · How we verify
Paxil®
At a glance
| Generic name | Paxil® |
|---|---|
| Sponsor | Teva Pharmaceuticals USA |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Paroxetine Hydrochloride 40 mg Tablets Under Fed Conditions (PHASE1)
- Paroxetine Hydrochloride 40 mg Tablets Under Fasting Conditions (PHASE1)
- Fasting Study of Paroxetine Hydrochloride Tablets 40 mg and Paxil® Tablets 40 mg (EARLY_PHASE1)
- Food Study of Paroxetine Hydrochloride Tablets 40 mg and Paxil® Tablets 40 mg (PHASE1)
- A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder (PHASE3)
- Psycho-biological Substrates of Therapeutic Benefit of Thermal Cure on Generalized Anxiety Disorders (PHASE4)
- A Study to Evaluate the Effect of Multiple Doses of Itraconazole, Phenytoin, and Paroxetine on the Single-Dose Pharmacokinetics of Poziotinib in Healthy Adult Participants (PHASE1)
- Bioequivalence Study of Paroxetine Tablets and Paxil® Under Fasting and Fed Conditions in Chinese Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Paxil® CI brief — competitive landscape report
- Paxil® updates RSS · CI watch RSS
- Teva Pharmaceuticals USA portfolio CI